Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ: ANIP )

58.46 +0.96 (+1.67%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 302,521
Open 57.94
Bid (Size) 56.69 (1)
Ask (Size) 60.25 (1)
Prev. Close 57.50
Today's Range 57.57 - 58.58
52wk Range 52.50 - 70.81
Shares Outstanding 24,422,240
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
+5.45%
+5.45%
1 Month
+9.58%
+9.58%
3 Month
-1.38%
-1.38%
6 Month
-5.82%
-5.82%
1 Year
+4.08%
+4.08%

More News

Read More
Where ANI Pharmaceuticals Stands With Analysts
Via Benzinga
A Peek at ANI Pharmaceuticals's Future Earnings
Via Benzinga
Critical Insights From ANI Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
Peeling Back The Layers: Exploring ANI Pharmaceuticals Through Analyst Insights
Via Benzinga
In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals
Via Benzinga
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
Via Benzinga
ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential
Via Benzinga
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Via Benzinga
ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
From ANI Pharmaceuticals, Inc. and Alimera Sciences, Inc.
Via Business Wire
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq - MORF), Desktop Metal, Inc. (NYSE - DM), Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR), PlayAGS, Incorporated (NYSE - AGS), RBAZ Bancorp, Inc. (OTCPK - RBAZ)
From Brodsky & Smith LLC
Via GlobeNewswire
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Nasdaq Records Worst Session Since April With Nvidia Plunging 7%: Dow Jones Sees Modest Gains Amid Mixed Market Close
Via Benzinga
Topics Stocks
Exposures US Equities
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts
Via Benzinga
Earnings Scheduled For February 29, 2024
Via Benzinga
ANI Pharmaceuticals's Earnings Outlook
Via Benzinga
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
Via InvestorPlace
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal
Via Benzinga
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Alphabet, Dover And 2 Other Stocks Insiders Are Selling
Via Benzinga
Drug Maker Organon Stock Scores Relative Strength Upgrade
Via Investor's Business Daily
Truist Securities Maintains Buy Rating for ANI Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.